This review summarizes the current diagnostic and therapeutic approaches for peripartum cardiomyopathy, with a focus on the safety and efficacy of various pharmacological agents during pregnancy and lactation.
No takes yet. Share an insight, caveat, or question.
Highlights need for pregnancy-safe therapies in peripartum cardiomyopathy; extends prior reviews but leaves open gaps in prospective data.
Vatutin et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: